Final Patent Interference Decision Favors Sarepta Therapeutics (SRPT) - Baird

September 21, 2016 6:46 AM EDT
Get Alerts SRPT Hot Sheet
Price: $61.41 +0.71%

Rating Summary:
    16 Buy, 8 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 13 | Down: 9 | New: 77
Trade SRPT Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Baird analyst, Brian Skorney, reiterated his Outperform rating on shares of Sarepta Therapeutic (NASDAQ: SRPT) after PTAB issued a decision on patent interference handing Sarepta its second win in two days. Though the decisions can be appealed, it looks like Sarepta may avoid paying royalties to BMRN in the U.S.

BioMarin and Sarepta were locked in three separate interference battles. Two had already been ruled on, with the methods of use interference favoring BioMarin and the composition of matter interference in exon-53 skipping favoring Sarepta. Both are currently in appeals. The final interference related to composition of matter in exon-51 skipping (106,008) was ruled on yesterday, and favored Sarepta.

No change to the price target of $102.

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $55.73 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, FDA

Related Entities

Robert W Baird

Add Your Comment